JP2024536132A5 - - Google Patents

Info

Publication number
JP2024536132A5
JP2024536132A5 JP2024519267A JP2024519267A JP2024536132A5 JP 2024536132 A5 JP2024536132 A5 JP 2024536132A5 JP 2024519267 A JP2024519267 A JP 2024519267A JP 2024519267 A JP2024519267 A JP 2024519267A JP 2024536132 A5 JP2024536132 A5 JP 2024536132A5
Authority
JP
Japan
Prior art keywords
antisense oligonucleotide
disease
related protein
polyq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536132A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/076748 external-priority patent/WO2023052317A1/en
Publication of JP2024536132A publication Critical patent/JP2024536132A/ja
Publication of JP2024536132A5 publication Critical patent/JP2024536132A5/ja
Pending legal-status Critical Current

Links

JP2024519267A 2021-09-29 2022-09-27 Rna編集方法 Pending JP2024536132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21199761.4 2021-09-29
EP21199761 2021-09-29
PCT/EP2022/076748 WO2023052317A1 (en) 2021-09-29 2022-09-27 Rna editing

Publications (2)

Publication Number Publication Date
JP2024536132A JP2024536132A (ja) 2024-10-04
JP2024536132A5 true JP2024536132A5 (cg-RX-API-DMAC10.html) 2025-10-02

Family

ID=78179173

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519267A Pending JP2024536132A (ja) 2021-09-29 2022-09-27 Rna編集方法

Country Status (7)

Country Link
US (1) US20240336919A1 (cg-RX-API-DMAC10.html)
EP (1) EP4408999A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536132A (cg-RX-API-DMAC10.html)
CN (1) CN118019848A (cg-RX-API-DMAC10.html)
AR (1) AR127158A1 (cg-RX-API-DMAC10.html)
TW (1) TW202329983A (cg-RX-API-DMAC10.html)
WO (1) WO2023052317A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202405143D0 (en) * 2024-04-11 2024-05-29 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of poly-q disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
JP2011510678A (ja) * 2008-02-08 2011-04-07 プロセンサ ホールディング ビーブイ Dna反復不安定性関連遺伝性障害を治療するための方法及び手段
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
EP2751269B1 (en) * 2011-08-29 2016-03-23 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
CN104254610A (zh) 2012-03-12 2014-12-31 桑塔里斯制药公司 调节atxn3表达的组合物和方法
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
PT2841578T (pt) * 2012-04-23 2017-08-10 Biomarin Tech Bv Resumo
EP3027617B1 (en) 2013-07-31 2026-02-18 Ionis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
EP3752611A1 (en) 2018-02-14 2020-12-23 ProQR Therapeutics II B.V. Antisense oligonucleotides for rna editing
AU2020210900B2 (en) * 2019-01-22 2025-04-24 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof
US20220098593A1 (en) * 2019-02-13 2022-03-31 Beam Therapeutics Inc. Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease

Similar Documents

Publication Publication Date Title
US5545729A (en) Stabilized ribozyme analogs
DE69514351T2 (de) Verzweigte Oligonukleotide als pathogenhemmende Mittel
JP7197463B2 (ja) Smn2の調節のための化合物及び方法
JP2021510511A5 (cg-RX-API-DMAC10.html)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2003523739A5 (cg-RX-API-DMAC10.html)
JP2022527105A5 (cg-RX-API-DMAC10.html)
JP2019525918A5 (cg-RX-API-DMAC10.html)
IL275903B1 (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
JP2024112834A5 (cg-RX-API-DMAC10.html)
JP7211933B2 (ja) 転写プロセシングの調節のための化合物及び方法
JP2022550979A5 (cg-RX-API-DMAC10.html)
TWI791868B (zh) 調節rtel1表現之寡核苷酸
US20240336919A1 (en) Rna editing
WO2025165891A1 (en) Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
JP2021510512A5 (cg-RX-API-DMAC10.html)
JP2023542889A (ja) 複数の標的を介して疼痛を処置するための治療用組成物
JP2024522272A5 (cg-RX-API-DMAC10.html)
JP2024522147A5 (cg-RX-API-DMAC10.html)
CN116670276A (zh) 用于通过多个靶标治疗疼痛的治疗组合物
US20240336920A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
JP2025518522A5 (cg-RX-API-DMAC10.html)
JP2021513851A5 (cg-RX-API-DMAC10.html)
WO2024046937A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof
JP2025508959A5 (cg-RX-API-DMAC10.html)